Advances in gene transfer methods have created the opportunity for development of gene therapy for human neurological disease such as Parkinsons disease (PD). One goal is to slow dopaminergic neuron loss and the success of such neuroprotective gene therapy is contingent on the development of safe and effective gene transfer vectors that can express a therapeutic gene over long periods of time in specific neuronal populations. The plasmid based herpes simplex virus (HSV) """"""""amplicon"""""""" vectors accommodate a large (9kb) typrosine hydroxylase (TH) promoter and provide highly selective and relatively long term (10 weeks) gene expression in dopamine (DA) neurons in the rat substantia nigra. But, HSV amplicon vector stocks also contain replication defective HSV helper virus which under some conditions and particularly at high multiplicities of infection produces cellular injury and death. The overall goals of this application are three fold:
Aim 1 will compare several complementary new methods to reduce and perhaps eliminate helper virus related toxicity and determine whether they provide increased efficiency and stability of amplicon transgene gene expression in vitro (in cultured primary neurons and astrocytes measuring titers of amplicon and helper, number of lac positive cells and cytotoxicity) and Aim 2 will test their efficacy in vivo using the long tyrosine hydroxylase promotor - b lacZ reporter amplicon (delivering virus to the striatum and scoring bgal expression (mRNA and protein) in DA neurons (TH positive) in the striatum and SN at 1,6, and 16 weeks after infection at several MOIs.). Finally Aim 3 will determine whether the approach of decreasing cytotoxicity leads to a more effective gene therapy. The applicant will construct new amplicon vectors carrying three candidate neuroprotective genes thought to work by different pathways, GDNF, BDNF and bcl-2, use the least cytotoxic system to produce infectious particles, and evaluate them in FluoroGold/6-OHDA lesioned rats, a progressive injury model of PD, examining gene expression characteristics (RNAse protection to measure vector mRNA levels, ELISA and immunostaining to measure gene products), neuroprotection (quantitation of FluoroGold labeled neurons) and neurochemical changes (levels of DA and metabolites-DOPAC, HVA as a measure of both intra and inter-neuron DA turnover and effects on serotonergic neurons with 5-HT, 5-HIAA) at 1 and 4 months after injection of viral stock.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS036420-02
Application #
2685775
Study Section
Special Emphasis Panel (ZRG1-NEUC (02))
Program Officer
Kerza-Kwiatecki, a P
Project Start
1997-04-01
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Rochester
Department
Neurology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Lee, Byoung Dae; Shin, Joo-Ho; VanKampen, Jackalina et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16:998-1000
Frazer, Maria E; Hughes, Jennifer E; Mastrangelo, Michael A et al. (2008) Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol Ther 16:845-53
Peterson, Elise B; Mastrangelo, Michael A; Federoff, Howard J et al. (2007) Neuronal specificity of HSV/sleeping beauty amplicon transduction in utero is driven primarily by tropism and cell type composition. Mol Ther 15:1848-55
Bowers, William J; Mastrangelo, Michael A; Howard, Darlene F et al. (2006) Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 13:580-8
Arvanian, Victor L; Bowers, William J; Anderson, Aileen et al. (2006) Combined delivery of neurotrophin-3 and NMDA receptors 2D subunit strengthens synaptic transmission in contused and staggered double hemisected spinal cord of neonatal rat. Exp Neurol 197:347-52
Arvanian, Victor L; Bowers, William J; Petruska, Jeffrey C et al. (2004) Viral delivery of NR2D subunits reduces Mg2+ block of NMDA receptor and restores NT-3-induced potentiation of AMPA-kainate responses in maturing rat motoneurons. J Neurophysiol 92:2394-404
Maguire-Zeiss, Kathleen A; Federoff, Howard J (2003) Convergent pathobiologic model of Parkinson's disease. Ann N Y Acad Sci 991:152-66
Tolba, Khaled A; Bowers, William J; Eling, David J et al. (2002) HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther 6:455-63
Tolba, Khaled A; Bowers, William J; Muller, Jacquelyn et al. (2002) Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62:6545-51
Richfield, Eric K; Thiruchelvam, Mona J; Cory-Slechta, Deborah A et al. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175:35-48

Showing the most recent 10 out of 16 publications